Rasmussen H H, Okita G T, Hartz R S, ten Eick R E
Reingold ECC Center, Department of Medicine, Northwestern University, Chicago, Illinois.
J Pharmacol Exp Ther. 1990 Jan;252(1):60-4.
The effect on the cardiac sarcolemmal Na+,K(+)-pump of therapeutic concentrations of cardiac glycosides administered long-term to humans in a clinical setting is uncertain. We therefore examined Na+,K(+)-pump activity in atrial tissue from two groups of patients undergoing cardiac surgery. Fourteen patients received digoxin long-term until the time of surgery and 12 "controls" never received digoxin. The hyperpolarization produced by the electrogenic Na+,K(+)-pump in response to an increase in intracellular Na+ activity was utilized to evaluate Na+,K+)-pump activity. After excision from the patients, specimens of atrial tissue were Na(+)-loaded by cooling to 2-3 degrees C for 1 hr. They were then warmed to 30 degrees C in Tyrode's solution containing 20 mM K+. After warming the resting membrane potential of the tissues from both groups transiently hyperpolarized to levels more negative than the equilibrium potential for K+ (= approximately -50 mV in 20 mM K+) indicating that the hyperpolarization was the consequence of electrogenic Na(+(-pumping. The maximal hyperpolarization of the resting potential in tissue from patients receiving digoxin long-term (-58.4 +/- 1.9 mV, mean +/- S.D.) was significantly (P less than .01) less negative than that in tissue from patients in the control group (-69.9 +/- 2.2 mV). These data support the hypothesis that digoxin, administered therapeutically in the clinical setting, can inhibit the Na(+)-pump in human heart, and that during long-term administration of digoxin the inhibition can be sustained.
在临床环境中,长期给予人类治疗浓度的强心苷对心肌细胞膜钠钾泵的影响尚不确定。因此,我们检测了两组接受心脏手术患者心房组织中的钠钾泵活性。14例患者长期服用地高辛直至手术时,12例“对照组”患者从未服用过地高辛。利用电生性钠钾泵对细胞内钠活性增加的反应所产生的超极化来评估钠钾泵活性。从患者身上切除心房组织标本后,将其冷却至2 - 3摄氏度1小时以加载钠。然后将它们置于含有20 mM钾的台氏液中并升温至30摄氏度。升温后,两组组织的静息膜电位均短暂超极化至比钾的平衡电位更负的水平(在20 mM钾中约为 - 50 mV),这表明超极化是电生性钠泵作用的结果。长期服用地高辛患者的组织中静息电位的最大超极化(-58.4 +/- 1.9 mV,平均值 +/- 标准差)明显(P <.01)不如对照组患者组织中的超极化程度(-69.9 +/- 2.2 mV)负。这些数据支持以下假设:在临床环境中治疗性使用的地高辛可抑制人心脏中的钠泵,并且在长期服用地高辛期间,这种抑制作用可以持续。